# US 2022/0251607 A1 · Metabolic engineering for microbial production of terpenoid products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0251607 A1
- Document ID: US20220251607A1
- Status: Published application
- Kind: A1
- Application number: 17/729,096
- Filed: 2022-04-26
- Published: 2022-08-11
- Earliest claimed: 2017-01-26
- Assignees: Manus Bio Inc.
- Applicants: Manus Bio Inc.
- Inventors: Ajikumar Parayil KUMARAN; Ryan LIM; Jason DONALD; Hsien-Chung TSENG; Christine Nicole S. SANTOS; Ryan PHILIPPE
- Web page: https://patentgrep.com/patent/US20220251607A1

## CPC

- C12P 5/007: {containing one or more isoprene units, i.e. terpenes (carotenes C12P23/00)}
- C12N 9/0008: {acting on the aldehyde or oxo group of donors (1.2)}
- C12N 9/0093: {acting on CH or CH2 groups (1.17)}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12P 7/04: acyclic
- C12Y 102/07001: Pyruvate synthase (1.2.7.1), i.e. pyruvate ferredoxin oxidoreductase
- C12Y 117/07001: (E)-4-Hydroxy-3-methylbut-2-enyl-diphosphate synthase (1.17.7.1)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to methods and bacterial strains for making terpene and terpenoid products, the bacterial strains having improved carbon pull through the MEP pathway and to a downstream recombinant synthesis pathway.

## Claims

### Claim 1

A method for production of a terpene or terpenoid product, comprising:
providing a bacterial strain that produces isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) through an upstream methylerythritol phosphate pathway (MEP pathway) and converts the IPP and DMAPP to a terpene or terpenoid product through a downstream synthesis pathway;
wherein IspG and IspH are overexpressed in the bacterial strain such that IspG activity and IspH activity are balanced to provide increased carbon flux to 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate (HMBPP) intermediate, while preventing accumulation of HMBPP at an amount that feeds back and reduces MEP pathway flux and terpene or terpenoid productivity; the strain optionally comprising one or more genetic modifications that enhance supply and/or transfer of electrons through the MEP pathway and/or to terpene and terpenoid products, and culturing the bacterial strain to produce the terpene or terpenoid product.

### Claim 2 (depends on 1)

The method of claim 1, wherein the bacterial strain is a bacteria selected from Escherichia spp., Bacillus spp., Corynebacterium Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

### Claim 3 (depends on 2)

The method of claim 2, wherein the bacterial strain is a species selected from Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, Vibrio natriegens, or Pseudomonas putida.

### Claim 4 (depends on 3)

The method of claim 3, wherein the bacterial strain is E. coli.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1 to 4, wherein the bacterial strain expresses dxs, ispD, ispE, and idi as recombinant genes, which are optionally expressed as an operon.

### Claim 6 (depends on 5)

The method of claim 5, wherein the bacterial strain expresses dxs, dxr, ispD, ispE, ispF, and idi as recombinant genes, which are optionally expressed as 1, 2, or 3 operons.

### Claim 7 (depends on 5, 6)

The method of claim 5 or 6, wherein the recombinant genes of the MEP pathway are expressed from one or more plasmids or are integrated into the chromosome.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1 to 7, wherein IspG and IspH are overexpressed by introducing recombinant ispG and ispH genes into the bacterial strain.

### Claim 9 (depends on 8)

The method of claim 8, wherein the recombinant IspG and/or IspH enzymes comprises one or more beneficial mutations, or is an ortholog having improved properties or activity under conditions used for culturing.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1 to 9, wherein the activity and/or expression of recombinant IspH is higher than the activity and/or expression of the recombinant IspG.

### Claim 11 (depends on 10)

The method of claim 10, wherein the expression of the recombinant IspH is higher than the expression of the recombinant IspG.

### Claim 12 (depends on 11)

The method of claim 11, wherein the recombinant IspH and IspG are expressed from an operon, with IspH gene positioned before the IspG gene in the operon.

### Claim 13 (depends on 12)

The method of claim 12, wherein the operon is expressed under control of a strong promoter.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1 to 13, wherein expression of the recombinant IspG and IspH enzymes are balanced by modifying the promoter strength, gene copy number, and/or ribosome binding site sequence of the ispG and/or ispH recombinant genes.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1 to 14, wherein HMBPP does not accumulate in cells substantially more than in a parent strain that does not comprise the recombinant ispG and ispH genes.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1 to 15, wherein the recombinant ispG and ispH genes are expressed from a plasmid or are integrated into the chromosome.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1 to 16, wherein the expression or activity of a recombinant idi gene is tuned to increase terpene or terpenoid production.

### Claim 18 (depends on 17)

The method of claim 17, wherein the expression of the recombinant idi gene is tuned by modifying the promoter strength, gene copy number, position in an operon, or ribosome binding site.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1 to 18, wherein HMBPP does not accumulate at greater than 10 mg/g of dry cell weight.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1 to 19, wherein the bacterial strain comprises one or more genetic modifications that enhance supply and/or transfer of electrons through the MEP pathway and/or to terpene and terpenoid products, and which optionally oxidizes pyruvate and/or reduces ferredoxin.

### Claim 21 (depends on 20)

The method of claim 20, wherein the bacterial strain contains an overexpression of an oxidoreductase.

### Claim 22 (depends on 21)

The method of claim 21, wherein the oxidoreductase is a pyruvate:flavodoxin oxidoreductase (PFOR).

### Claim 23 (depends on 22)

The method of claim 22, wherein the PFOR is YdbK.

### Claim 24 (depends on 21)

The method of claim 21, wherein the bacterial strain comprises a recombinant YdbK gene.

### Claim 25 (depends on 24)

The method of claim 24, wherein the recombinant YdbK gene is integrated into the chromosome or expressed from a plasmid, which is optionally under the control of a weak or intermediate strength promoter.

### Claim 26 (depends on 21, 22, 23, 24, 25)

The method of any one of claims 21 to 25, wherein the strain comprises one or more P450 enzymes for the production of a terpenoid compound.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21 to 26, further comprising an overexpression of one or more of a flavodoxin, flavodoxin reductase, ferredoxin, and ferredoxin reductase.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1 to 27, wherein the expression or activity of IspG and IspH is balanced with respect to the expression or activity of Dxr, Dxs, IspD, IspE and IspF to reduce MEcPP metabolite in the culture.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1 to 27, wherein the bacterial strain comprises an overexpression of PgpB and/or NudB.

### Claim 30 (depends on 29)

The method of claim 29, wherein the bacterial strain expresses at least one recombinant pgpB and/or nudB gene.

### Claim 31 (depends on 29)

The method of claim 29, wherein the expression of the recombinant PgpB and/or NudB is tuned to provide higher terpene or terpenoid product titer, optionally by varying promoter strength, gene copy number, position in an operon, and/or ribosome binding site.

### Claim 32 (depends on 31)

The method of claim 31, wherein the recombinant PgpB and/or NudB is expressed under control of a weak or intermediate strength promoter.

### Claim 33 (depends on 30, 31, 32)

The method of any one of claims 30 to 32, wherein the recombinant pgpB or nudB is integrated into the chromosome or expressed from a plasmid.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1 to 33, wherein the bacterial strain has one or more additional modifications to increase co-factor availability or turnover, the one or more additional modifications optionally selected from recombinant expression of a glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR); overexpression of ydhV and/or ydhY; downregulation, inactivation, or deletion of gshA; and recombinant expression of CHAC1 and/or CHAC2.

### Claim 35

A method for draining excess carbon flux from the MEP pathway in a bacterial cell, comprising:
providing a bacterial strain that produces isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) through an upstream methylerythritol phosphate pathway (MEP pathway) and optionally converts the IPP and DMAPP to a terpene or terpenoid product through a downstream synthesis pathway;
wherein the bacterial strain overexpresses one or more MEP pathway genes and overexpresses PgpB and/or NudB,
culturing the bacterial strain to produce MEP carbon.

### Claim 36 (depends on 35)

The method of claim 35, wherein the bacterial strain is a bacteria selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

### Claim 37 (depends on 35)

The method of claim 35, wherein the bacterial strain is a species selected from Escherichia coli, Bacillus subtilis, Corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymornonas mobilis, Vibrio natriegens, or Pseuclomonas putida.

### Claim 38 (depends on 37)

The method of claim 37, wherein the bacterial strain is E. coli.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35 to 38, wherein he bacterial strain expresses at least one recombinant PgpB and/or NudB gene.

### Claim 40 (depends on 39)

The method of claim 39, wherein the expression of the recombinant PgpB and/or NudB is tuned to provide higher terpene or terpenoid product titer, optionally by varying promoter strength, gene copy number, position in an operon, and/or ribosome binding site.

### Claim 41 (depends on 40)

The method of claim 40, wherein the recombinant PgpB and/or NudB is expressed under control of a weak or intermediate strength promoter.

### Claim 42 (depends on 39, 40, 41)

The method of any one of claims 39 to 41, wherein the recombinant PgpB or NudB is integrated into the chromosome or expressed from a plasmid.

### Claim 43 (depends on 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 35 to 42, wherein the bacterial strain overexpresses IspG and IspH such that IspG activity and IspH activity are balanced to provide increased carbon flux to HMBPP intermediate, while preventing accumulation of HMBPP at an amount that substantially reduces cell growth, viability, MEP flux, or product titer.

### Claim 44 (depends on 43)

The method of claim 43, wherein HMBPP does not accumulate at greater than 10 mg/g of dry cell weight.

### Claim 45 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 35 to 44, wherein the bacterial strain expresses dxs, ispD, ispF, and idi as recombinant genes, which are optionally expressed as an operon.

### Claim 46 (depends on 45)

The method of claim 45, wherein the bacterial strain expresses dxs, dxr, ispD, ispE, ispF, and idi as recombinant genes, which are optionally expressed as 1, 2, or 3 operons.

### Claim 47 (depends on 45, 46)

The method of claim 45 or 46, wherein the recombinant genes of the MEP pathway are expressed from one or more plasmids or are integrated into the chromosome.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43 to 47, wherein IspG and IspH are overexpressed by introducing at least one recombinant IspG and IspH gene into the bacterial strain.

### Claim 49 (depends on 48)

The method of claim 48, wherein the activity and/or expression of recombinant IspH is higher than the activity and/or expression of the recombinant ispG.

### Claim 50 (depends on 49)

The method of claim 49, wherein the recombinant IspH and ispG are expressed as an operon, with IspH positioned before IspG in the operon, wherein the operon is optionally expressed under control of a strong promoter.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 43 to 50, wherein the recombinant ispG and IspH genes are expressed from a plasmid or are integrated into the chromosome.

### Claim 52 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 35 to 51, wherein the expression or activity of a recombinant Idi gene is tuned to increase terpene or terpenoid production.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 42 to 52, wherein the bacterial strain contains an overexpression of an oxidoreductase.

### Claim 54 (depends on 53)

The method of claim 53, wherein the oxidoreductase is a pyruvate:flavodoxin oxidoreductase (PFOR),

### Claim 55 (depends on 54)

The method of claim 54, wherein the PFOR is YdbK.

### Claim 56 (depends on 55)

The method of claim 55, wherein a recombinant YdbK gene is integrated into the chromosome or expressed from a plasmid.

### Claim 57 (depends on 53, 54, 55, 56)

The method of any one of claims 53 to 56, wherein the strain comprises one or more P450 enzymes for the production of a terpenoid compound.

### Claim 58 (depends on 53, 54, 55, 56, 57)

The method of any one of claims 53 to 57, further comprising an overexpression of one or more of a flavodoxin, flavodoxin reductase, ferredoxin, and ferredoxin reductase.

### Claim 59 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 35 to 58, wherein the bacterial strain has one or more additional modifications to increase co-factor availability or turnover, the one or more additional modifications optionally selected from recombinant expression of a glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR); overexpression of ydhV and/or ydhY; downregulation, inactivation, or deletion of gshA; and recombinant expression of CHAC1 and/or CHAC2.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1 to 59, wherein the bacterial strain has reduced or eliminated PDH mediated conversion of pyruvate to acetyl-CoA.

### Claim 61 (depends on 60)

The method of claim 60, wherein the bacterial strain expresses a mutant aceE, wherein the mutation is G267C.

### Claim 62 (depends on 60)

The method of claim 60, wherein the bacterial strain has a deletion or inactivation of aceE.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1 to 62, wherein the bacterial strain over expresses one or more non-native fdx and/or fldA homologs.

### Claim 64 (depends on 63)

The method of claim 63, wherein the fdx homolog is selected from Hm.fdx1 (Heliobacterium modesticaldum), Pa.fdx (Pseudomonas aeruginosa), Cv.fdx (Allochromatium vinosum), Ca.fdx (Clostridium acetobulylieum), Cp.fdx (Clostridium pasteurianum), Ev2. fdx (Ectothiorhodospira shaposhnikovii), Pp1.fdx (Pseudomonas putida) and Pp2.fdx (Pseudomonas putida), or a derivative of any of the foregoing.

### Claim 65 (depends on 63)

The method of claim 63, wherein the fidA homolog is selected from Ac.fldA2 (Azotobacter chroococcum), Av.fldA2 (Azotobacter vinelandii), and Bs.fldA (B. subtilis), or a derivative thereof.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1 to 65, wherein the terpene or terpenoid product comprises at least one compound selected from: Farnesene, Amorphadiene, Artemisinic acid, Artemisinin, Bisabolol, Bisabolene, alpha-Sinensal, beta-Thujone, Camphor, Carveol, Carvone, Cineole, Citral, Citronellal, Cubebol, Geraniol, Limonene, Menthol, Menthone, Myrcene, Nootkatone, Nootkatol, Patchouli, Piperitone, Rose oxide, Sabinene, Steviol, Steviol glycoside (including Rebaudioside D or Rebaudioside M), Taxadiene, Thymol, and Valencene.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 1 to 66, wherein the strain comprises a terpene synthase enzyme that has one or more modifications to improve one or more of enzyme kinetics, terpene or terpenoid product profile, stability, and temperature tolerance.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1 to 67, wherein the strain is cultured with a C1, C2, C3, C4, C5, or C6 carbon source.

### Claim 69 (depends on 68)

The method of claim 68, wherein the carbon source is glucose, sucrose, or glycerol.

### Claim 70 (depends on 68, 69)

The method of claim 68 or 69, wherein the bacterial strain is cultured at a temperature between 22° C. and 37° C.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 1 to 70, wherein culturing step is a fed-batch process comprising a first phase where bacterial biomass is created, followed by a terpene or terpenoid production phase.

### Claim 72 (depends on 71)

The method of claim 71, wherein the culture is at least about 100 L.

### Claim 73 (depends on 72)

The method of claim 72, wherein the culture is from about 300 L to about 1,000,000 L.

### Claim 74 (depends on 68, 69, 70, 71, 72, 73)

The method of any one of claims 68 to 73, wherein the culture is maintained under aerobic conditions.

### Claim 75 (depends on 74)

The method of claim 74, wherein the culture is maintained under micro-aerobic conditions.

### Claim 76 (depends on 74, 75)

The method of claim 74 or 75, wherein the biomass production phase occurs under aerobic conditions, followed by reducing the oxygen levels after from about 10 to about 20 hours.

### Claim 77 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 68 to 76, wherein the production phase includes feeding a nitrogen source, which optionally comprises ammonium hydroxide.

### Claim 78 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 68 to 77, wherein the production phase includes feeding a carbon source, which optionally comprises glucose, sucrose, and/or glycerol.

### Claim 79 (depends on 76, 77, 78)

The method of any one of claims 76 to 78, wherein the nitrogen and carbon feeding is initiated when a predetermined amount of batch media is consumed.

### Claim 80 (depends on 78, 79)

The method of claim 78 or 79, wherein the nitrogen feed rate is from about 8 L per hour to about 20 L per hour.

### Claim 81 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 68 to 80, further comprising, monitoring or testing the accumulation of indole in the culture.

### Claim 82 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 68 to 81, comprising monitoring or testing the accumulation of MEcPP in the culture.

### Claim 83 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 68 to 82, further comprising, monitoring or testing the level of HMBPP in the cells.

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method of any one of claims 1 to 83, further comprising, recovering the terpene or terpenoid product.

### Claim 85 (depends on 84)

The method of claim 84, wherein the product is a volatile terpene or terpenoid product.

### Claim 86 (depends on 85)

The method of claim 85, wherein the terpene or terpenoid product is recovered from an organic or hydrophobic phase that is mechanically separated from the culture.

### Claim 87 (depends on 86)

The method of claim 86, wherein the terpene or terpenoid product is harvested from the liquid and/or solid phase.

### Claim 88 (depends on 85, 86, 87)

The method of any one of claims 85 to 87, wherein the product is purified by distillation, which is optionally simple distillation, steam distillation, fractional distillation, wipe-film distillation, or continuous distillation.

### Claim 89 (depends on 85, 86, 87, 88)

The method of any one of claims 85 to 88, wherein the product is purified by sequential extraction and purification.

### Claim 90 (depends on 85, 86, 87, 88, 89)

The method of any one of claims 85 to 89, wherein the product is purified by chromatography-based separation and recovery, which is optionally supercritical fluid chromatography.

### Claim 91 (depends on 84)

The method of claim 84, wherein the product is a non-volatile terpene or terpenoid product.

### Claim 92 (depends on 91)

The method of claim 91, wherein the product is an extracellular product recovered from the culture medium.

### Claim 93 (depends on 91)

The method of claim 91, wherein the product is an intracellular product recovered from harvested cell material.

### Claim 94 (depends on 91, 92, 93)

The method of any one of claims 91 to 93, wherein the product is poorly soluble and is recovered by filtration, optionally with solvent extraction.

### Claim 95 (depends on 94)

The method of claim 94, wherein the solvent is ethanol.

### Claim 96 (depends on 91, 92, 93, 94, 95)

The method of any one of claims 91 to 95, wherein the product is recovered by chromatography-based separation, which is optionally liquid chromatography.

### Claim 97 (depends on 96)

The method of claim 96, wherein the product is recovered by filtration.

### Claim 98 (depends on 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 89 to 96, wherein the product is recovered by sequential extraction and purification.

### Claim 99 (depends on 92, 93)

The method of claim 92 or 93, wherein the product is crystallized out of solution.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

A method for making an industrial or consumer product, comprising, incorporating the terpene or terpenoid made according to the method of any one of claims 1 to 100 into said industrial or consumer product.

### Claim 101 (depends on 100)

The method of claim 100, wherein the industrial or consumer product is a flavor product, a fragrance product, a sweetener, a cosmetic, a cleaning product, a detergent or soap, or a pest control product.

### Claim 102 (depends on 100)

The method of claim 100, wherein the industrial or consumer product is a food, beverage, texturant, pharmaceutical, tobacco product, nutraceutical, oral hygiene product, or cosmetic product.

### Claim 103 (depends on 1, 102)

The method of any one of claims 1 to 102, wherein the bacterial strain or cell overexpresses one or more of geranyl diphosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), and geranylgeranyl diphosphate synthase (GGPPS).

### Claim 104

A bacterial strain having one or more genetic modifications that increase production of products from isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) precursors; the bacterial strain producing isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) through an MEP pathway, and the MEP pathway comprising one or more overexpressed genes; the strain converting the IPP and DMAPP to a terpene or terpenoid product through a downstream synthesis pathway; wherein said genetic modifications comprise:
(a) recombinant or modified IspG and IspH enzymes, the IspG and IspH enzymes having balanced expression or activity to prevent accumulation of HMBPP intermediate,
(b) a recombinant or modified gene encoding an enzyme that enhances supply and/or transfer of electrons through the MEP pathway and/or to terpene or terpenoid products, which is optionally an overexpression of a YdbK gene and optionally with a non-native fdx and/or fldA homolog,
(c) an inactivation or deletion, or reduced expression or activity, of aceE or aceE enzyme complex, and optionally
(d) a recombinant or modified idi gene to tune activity for higher terpene or terpenoid production.

### Claim 105 (depends on 104)

The bacterial strain of claim 104, wherein the bacterial strain is a bacteria selected from Escherichia spp., Bacillus spp., Corynebacterium spp., Rhodobacter spp., Zymomonas spp., Vibrio spp., and Pseudomonas spp.

### Claim 106 (depends on 105)

The bacterial strain of claim 105, wherein the bacterial strain is a species selected from Escherichia coli, Bacillus subtillus, corynebacterium glutamicum, Rhodobacter capsulatus, Rhodobacter sphaeroides, Zymomonas mobilis, Vibrio natriegens, or Pseudomonas putida.

### Claim 107 (depends on 106)

The bacterial strain of claim 106, wherein the bacterial strain is E. coli.

### Claim 108 (depends on 104, 105, 106, 107)

The bacterial strain of any one of claims 104 to 107, wherein the bacterial strain expresses dxs, ispD, ispF, and idi as recombinant genes, which are optionally expressed as an operon.

### Claim 109 (depends on 108)

The bacterial strain of claim 108, wherein the bacterial strain expresses dxs, dxr, ispD, ispE, ispF, and idi as recombinant genes, which are optionally expressed as 1, 2, or 3 operons.

### Claim 110 (depends on 108, 109)

The bacterial strain of claim 108 or 109, wherein the recombinant genes of the MEP pathway are expressed from one or more plasmids or are integrated into the chromosome.

### Claim 111 (depends on 104, 105, 106, 107, 108, 109, 110)

The bacterial strain of any one of claims 104 to 110, wherein HMBPP does not accumulate at greater than 10 mg/g of dry cell weight.

### Claim 112 (depends on 104, 105, 106, 107, 108, 109, 110, 111)

The bacterial strain of any one of claims 104 to 111, wherein the recombinant ispG and ispH genes comprise one or more beneficial mutations, or encode an IspG or IspH ortholog having improved properties or activity.

### Claim 113 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112)

The bacterial strain of any one of claims 104 to 112, wherein the expression of recombinant IspH is higher than the expression of the recombinant IspG.

### Claim 114 (depends on 113)

The bacterial strain of claim 113, wherein the recombinant ispH and ispG are expressed as an operon, with ispH positioned before ispG in the operon.

### Claim 115 (depends on 114)

The bacterial strain of claim 114, wherein the operon is expressed under control of a strong promoter.

### Claim 116 (depends on 112, 113, 114, 115)

The bacterial strain of any one of claims 112 to 115, wherein the recombinant ispG and ispH genes are expressed from a plasmid or are integrated into the chromosome.

### Claim 117 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)

The bacterial strain of any one of claims 104 to 116, wherein the expression or activity of a recombinant idi gene is tuned to increase terpene or terpenoid production, optionally by modifying the promoter strength, gene copy number, position in an operon, or ribosome binding site.

### Claim 118 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The bacterial strain of any one of claims 104 to 117, wherein the bacterial strain contains an overexpression of an oxidoreductase.

### Claim 119 (depends on 118)

The bacterial strain of claim 118, wherein the oxidoreductase is a pyruvate:flavodoxin oxidoreductase (PFOR).

### Claim 120 (depends on 119)

The bacterial strain of claim 119, wherein the PFOR is YdbK.

### Claim 121 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The bacterial strain of any one of claims 104 to 120, wherein the strain contains an enzyme that oxidizes pyruvate and/or reduces ferredoxin, which is optionally a recombinant YdbK gene, and which is optionally integrated into the chromosome or expressed from a plasmid.

### Claim 122 (depends on 121)

The bacterial strain of claim 121, wherein the strain comprises one or more P450 enzymes for the production of a terpenoid compound.

### Claim 123 (depends on 121, 122)

The bacterial strain of claim 121 or 122, further comprising an overexpression of one or more of a flavodoxin, flavodoxin reductase, ferredoxin, and ferredoxin reductase.

### Claim 124 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123)

The bacterial strain of any one of claims 104 to 123, wherein the expression of the recombinant pgpB and/or nudB is tuned to provide higher terpene or terpenoid product titer, optionally by varying the promoter strength, gene copy number, position in an operon, and/or ribosome binding site.

### Claim 125 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124)

The bacterial strain of any one of claims 104 to 124, wherein the strain has one or more additional modifications selected from: recombinant expression of a glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR); overexpression of ydhV and/or ydhY; downregulation, inactivation, or deletion of gshA; and recombinant expression of CHAC1 and/or CHAC2.

### Claim 126 (depends on 125)

The bacterial strain of claim 125, wherein the recombinant pgpB and/or nudB is expressed under control of a weak or intermediate strength promoter.

### Claim 127 (depends on 126)

The bacterial strain of claim 126, wherein the recombinant pgpB or nudB is integrated into the chromosome or expressed from a plasmid.

### Claim 128 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127)

The bacterial strain of any one of claims 104 to 127, wherein the bacterial strain has reduced or eliminated PDH-mediated conversion of pyruvate to acetyl-CoA.

### Claim 129 (depends on 128)

The bacterial strain of claim 128, wherein the bacterial strain expresses a mutant aceE, wherein the mutation is G267C.

### Claim 130 (depends on 129)

The bacterial strain of claim 129, wherein the bacterial strain has a deletion or inactivation of aceE.

### Claim 131 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130)

The bacterial strain of any one of claims 104 to 130, wherein the bacterial strain overexpresses one or more non-native fdx and/or fldA homolog.

### Claim 132 (depends on 131)

The bacterial strain of claim 131, wherein the non-native fdx homolog is selected from Hm.fdx1 (Heliobacterium modesticaldum), Pa.fdx (Pseudomonas aeruginosa), Cv.fdx (Allochromatium vinosum), Ca.fdx (Clostridium acetobutylicum), Cp.fdx (Clostridium pasteurianum), and Ev2.fdx (Ectothiorhodospira shaposhnikovii), Ppl.fdx (Pseudomonas putida) and Pp2.fdx (Pseudomonas putida), or derivative of any of the foregoing.

### Claim 133 (depends on 132)

The bacterial strain of claim 132, wherein the fldA homolog is selected from Ac.fldA2 (Azotobacter chroococcum), Av.fldA2 (Azotobacter vinelandii), and Bs.fldA. (B. subtilis), or a derivative thereof.

### Claim 134 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The bacterial strain of any one of claims 104 to 133, wherein the terpene or terpenoid product comprises at least one compound selected from: Farnesene, Amorphadiene, Artemisinic acid, Artemisinin, Bisabolol, Bisabolene, alpha-Sinensal, beta-Thujone, Camphor, Carveol, Carvone, Cineole, Citral, Citronellal, Cubebol, Geraniol, Linionene, Menthol, Menthane, Myrcene, Nootkatone, Nootkatol, Patchouli, Piperitone, Rose oxide, Sabinene, Steviol, Steviol glycoside (including Rebaudioside D or Rebaudioside M), Taxadiene, Thymol, and Valencene.

### Claim 135 (depends on 134)

The bacterial strain of claim 134, wherein the strain comprises a terpene synthase enzyme that has one or more modifications to improve one or more of enzyme kinetics, terpene or terpenoid product profile, stability, and temperature tolerance.

### Claim 136 (depends on 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The bacterial strain of any one of claims 104-135, wherein the bacterial strain overexpresses one or more of geranyl diphosphate synthase (GPPS), farnesyl diphosphate synthase (FPPS), and geranylgeranyl diphosphate synthase (GGPPS).
